Dyslipidemia in patients with diabetes mellitus – rules of pharmacotherapy from the cardiologist point of view Review article
Article Sidebar
Published:
Sep 30, 2011
Keywords:
diabetes, atherogenic dyslipidemia, polypharmacotherapy of dyslipidemia
Main Article Content
Abstract
Dyslipidemia is one of the most common risk factor of cardiovascular diseases. Moreover, cardiovascular diseases are the first cause of death in patients with diabetes mellitus. In those patients low HDL and very high triglycerides concentrations are common findings. As far as LDL concentration is concern it may by not elevated, but this lipoproteins are changed. It is so called atherogenic dyslipidemia. Statin should be given to every patient with diabetes, in practice however even high doses of strong statins fail to reduce LDL to therapeutic level. Therefore in some patients polypharmacotherapy of dyslipidemia should be taken into consideration.
Article Details
How to Cite
Wełnicki , M., & Kuch , M. (2011). Dyslipidemia in patients with diabetes mellitus – rules of pharmacotherapy from the cardiologist point of view. Medycyna Faktow (J EBM), 4(3(12), 54-58. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2521
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Standards of Medical Care in Diabetes 2011. American Diabetes Association. Diabetes Care 2011 January; 34(suppl. 1).
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2011; 12(supl. A).
3. Aktualne problemy terapii dyslipidemii w Polsce – Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń 2011; 8(1): 1-4.
4. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32: 1769-1818 [doi:10.1093/eurheartj/ehr158].
5. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
6. Farnier M., Averna M., Missault L. et al.: Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN-CROSS study. Int. J. Clin. Pract. [doi: 10.1111/j.1742-1241.2009.02022.x].
7. SHARP Collaborative Group. The Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 2010; 160: 785-794.e10.
8. Villines T.C. et al.: The ARBITER 6-HALTS Trial (Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010 April 8 [Epub ahead of print]. PMID: 20399059.
9. Chapman M.J., Ginsberg H.N., Amarenco P. et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal [doi: 10.1093/eurheartj/ehr112].
10. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362: 1563-1574.
11. Scott R., O’Brien R., Fulcher G., Pardy C., D’Emden M., Tse D., Taskinen M.R., Ehnholm C., Keech A.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009; 32: 493-498.
12. Saha S.A., Arora R.R.: Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – a pooled meta-analysis of randomized placebo-controlled clinical trials. Int. J. Cardiol. 2009; 141: 157-166.
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2011; 12(supl. A).
3. Aktualne problemy terapii dyslipidemii w Polsce – Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń 2011; 8(1): 1-4.
4. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32: 1769-1818 [doi:10.1093/eurheartj/ehr158].
5. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
6. Farnier M., Averna M., Missault L. et al.: Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN-CROSS study. Int. J. Clin. Pract. [doi: 10.1111/j.1742-1241.2009.02022.x].
7. SHARP Collaborative Group. The Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 2010; 160: 785-794.e10.
8. Villines T.C. et al.: The ARBITER 6-HALTS Trial (Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010 April 8 [Epub ahead of print]. PMID: 20399059.
9. Chapman M.J., Ginsberg H.N., Amarenco P. et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal [doi: 10.1093/eurheartj/ehr112].
10. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362: 1563-1574.
11. Scott R., O’Brien R., Fulcher G., Pardy C., D’Emden M., Tse D., Taskinen M.R., Ehnholm C., Keech A.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009; 32: 493-498.
12. Saha S.A., Arora R.R.: Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – a pooled meta-analysis of randomized placebo-controlled clinical trials. Int. J. Cardiol. 2009; 141: 157-166.